Compare Abbott Laboratories (ABT) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Abbott Laboratories trades at $95.55 (market cap $166.94B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.23. The key difference: Abbott Laboratories pays a 2.63% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | JEPQ | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $61.46 |
52-Week Low | $82.57 | $53.77 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
JEPQ trades at $60.16, up 1.3% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on the Nasdaq-100 to generate monthly income, with recent dividends of $0.64, $0.56, and $0.59. Media coverage highlights its role in retirement portfolios but notes performance trade-offs versus pure growth ETFs.
Outlook is mixed: strong income appeal for retirees balances against capped upside in tech rallies. Key risks include underperformance in bull markets and dependence on option premiums. Investors prioritize income over capital appreciation with this strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
